Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

Nature Biotechnology

Volumn 30, Issue 3, 2012, Pages 283-288

  Wahlberg, Elisabet ^a,e   Karlberg, Tobias ^a   Kouznetsova, Ekaterina ^a,f   Markova, Natalia ^a,c   Macchiarulo, Antonio ^b   Thorsell, Ann Gerd ^a   Pol, Ewa ^c   Frostell, Åsa ^c   Ekblad, Torun ^a   Öncü, Delal ^d   Kull, Björn ^d   Robertson, Graeme Michael ^b   Pellicciari, Roberto ^b   Schüler, Herwig ^a   Weigelt, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c GE Healthcare Bio Sciences AB   (Sweden)

^d Actar AB   (Sweden)

^e Faculty of Natural Resources and Agricultural Sciences   (Sweden)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABT-888; CANCER THERAPEUTICS; CATALYTIC DOMAINS; CHEMICAL PROFILING; CLINICAL TRIAL; INHIBITORY ACTIVITY; LIGAND COMPLEXES; MULTIPLE TARGETS; PARP-INHIBITOR; RESEARCH REAGENTS; SMALL-MOLECULE INHIBITORS; TANKYRASE; X RAY CRYSTAL STRUCTURES;

COMPLEXATION; FUNCTIONAL POLYMERS;

CHEMICAL COMPOUNDS;

6(5H) PHENANTHRIDINONE; ENZYME INHIBITOR; KU 0058948; KU 0058949; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHENANTHRIDINE DERIVATIVE; RUCAPARIB; TANKYRASE; TANKYRASE INHIBITOR; TIQ A; UNCLASSIFIED DRUG; VELIPARIB; XAV 939;

ARTICLE; CANCER THERAPY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES; TANKYRASES;

EID: 84857939963     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2121     Document Type: Article

References (43)

1. Hottiger, M.O., Hassa, P.O., Lüscher, B., Schüler, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP- ribosyltransferases. Trends Biochem. Sci. 35, 208-219 (2010).
2. Amé, J.C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882-893 (2004).
3. Sugimura, T., Fujimura, S., Hasegawa, S. & Kawamura, Y. Polymerization of the adenosine 5&πριμε;-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim. Biophys. Acta 138, 438-441 (1967).
4. Otto, H. et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 6, 139 (2005).
5. Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57-69 (2008).
6. Hassa, P.O. & Hottiger, M.O. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046-3082 (2008).
7. Yélamos, J., Schreiber, V. & Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 14, 169-178 (2008).
8. Calabrese, C.R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56-67 (2004).
9. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
10. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
11. Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res. 68, 10021-10023 (2008).
12. Jagtap, P. & Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421-440 (2005).
13. Kauppinen, T.M. & Swanson, R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145, 1267-1272 (2007).
14. Strosznajder, R.P., Czubowicz, K., Jesko, H. & Strosznajder, J.B. Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology. Mol. Neurobiol. 41, 187-196 (2010).
15. Ba, X. & Garg, N.J. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am. J. Pathol. 178, 946-955 (2011).
16. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484-1487 (1998).
17. McCabe, N. et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 28, 1465-1470 (2009).
18. Huang, S.M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
19. Purnell, M.R. & Whish, W.J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 185, 775-777 (1980).
20. Papeo, G. et al. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 19, 1377-1400 (2009).
21. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
22. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
23. Carden, C.P., Yap, T.A. & Kaye, S.B. PARP inhibition: targeting the Achilles′ heel of DNA repair to treat germline and sporadic ovarian cancers. Curr. Opin. Oncol. 22, 473-480 (2010).
24. Frye, S.V. The art of the chemical probe. Nat. Chem. Biol. 6, 159-161 (2010).
25. Ruf, A., Mennissier de Murcia, J., de Murcia, G. & Schulz, G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA 93, 7481-7485 (1996).
26. Bell, C.E. & Eisenberg, D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35, 1137-1149 (1996).
27. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835-15840 (2006).
28. Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007).
29. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
30. Plummer, R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res. 16, 4527-4531 (2010).
31. Pellicciari, R. et al. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco 58, 851-858 (2003).
32. Chiarugi, A. et al. Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. 305, 943-949 (2003).
33. Hans, C.P. et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J. Pharmacol. Exp. Ther. 329, 150-158 (2009).
34. Lehtiö, L. et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52, 3108-3111 (2009).
35. Karlberg, T. et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem. 53, 5352-5355 (2010).
36. Karlberg, T., Hammarström, M., Schütz, P., Svensson, L. & Schüler, H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 49, 1056-1058 (2010).
37. Lehtiö, L. et al. Zinc binding catalytic domain of human tankyrase 1. J. Mol. Biol. 379, 136-145 (2008).
38. Iwashita, A. et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett. 579, 1389-1393 (2005).
39. Yu, M. et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982-1993 (2005).
40. Chou, H.Y., Chou, H.T. & Lee, S.C. CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10). J. Biol. Chem. 281, 15201-15207 (2006).
41. Citarelli, M., Teotia, S. & Lamb, R.S. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol. 10, 308 (2010).
42. Edwards, A.M. et al. Too many roads not taken. Nature 470, 163-165 (2011).
43. Ringner, M. What is principal component analysis? Nat. Biotechnol. 26, 303-304 (2008).